Venus Medtech (Hangzhou) Inc. (HKG:2500)

Market Cap	446.66M -56.4%
Revenue (ttm)	294.56M -40.3%
Net Income	-535.94M
EPS	-1.22
Shares Out	437.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	174,000
Open	0.970
Previous Close	1.000
Day's Range	0.970 - 1.020
52-Week Range	0.940 - 3.860
Beta	1.22
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 557
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2500

Financial Performance

In 2025, Venus Medtech (Hangzhou)'s revenue was 306.79 million, a decrease of -34.84% compared to the previous year's 470.83 million. Losses were -407.69 million, -42.92% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error